TnFerade biologic: Preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene

Cancer Gene Therapy

Volumn 9, Issue 11, 2002, Pages 951-957

  Rasmussen, Henrik ^a   Rasmussen, Camilla ^a   Lempicki, Maria ^a   Durham, Rebecca ^a   Brough, Douglas ^a   King, C Richter ^a   Weichselbaum, Ralph ^b  

^a GENVEC INC   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Cancer gene therapy; Preclinical toxicology; Radiation inducible promoter; TNF

Indexed keywords

ADENOVIRUS VECTOR; EARLY GROWTH RESPONSE FACTOR 1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPSY; CANCER; CANCER RADIOTHERAPY; CONTROLLED STUDY; DRUG POTENCY; DRUG TOLERABILITY; GENE THERAPY; INJECTION SITE; MOUSE; MOUSE STRAIN; NECROSIS; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SKIN ULCER; SQUAMOUS CELL CARCINOMA; VIRUS GENOME; XENOGRAFT;

ADENOVIRIDAE; ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL SURVIVAL; GENE EXPRESSION REGULATION; GENE THERAPY; HUMANS; LARYNGEAL NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; PROMOTER REGIONS (GENETICS); SEQUENCE DELETION; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

ADENOVIRIDAE; ALPHAVIRUS; ANIMALIA; MUS MUSCULUS;

EID: 0036841845     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700518     Document Type: Article

References (34)

1. Balkwell FR, Lee A, Aldam G, et al. Human tumor xenografts treated with recombinant human tumor necrosis factor alone or in combination with interferon. Cancer Res. 0996;46:3990-3993
2. Asher A, Mule JJ, Reichert CM, et al. Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol. 1987;138:963-974
3. Renard N, Lienard D, Lespagnard L, et al. Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumor necrosis factor alpha (rTNA alpha). Int J Cancer. 1994;57:656-663.
4. Fukumura D, Salehi HA, Witwer B, et al. Tumor necrosis factor alpha-induced leukocyte adhesion in normal and tumor vessels: Effect of tumor type, transplantation site, and host strain. Cancer Res. 1995;55:4824-4829.
5. Hallahan DE, Vokes EE, Rubin SJ, et al. Phase I dose-escalation study of tumor necrosis factor-alpha and concomitant radiation therapy. Cancer J Sci Am. 1995;1:204-209.
6. Chapman PB, Lester TJ, Casper ES, et al. Clinical pharmacology of human tumor necrosis factor in patients with advanced cancer. J Clin Oncol. 1987;5:1942-1951.
7. Feinberg B, Kurzrock R, Talpaz M, et al. A phase I trial of intravenously administered recombinant tumor necrosis factor-alpha in cancer patients. J Clin Oncol. 1988;6:1328-1334.
8. Springs DR, Sherman ML, Michie H, et al. Recombinant tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study. J Natl Cancer Inst. 1988;80:1039-1044.
9. Lienard D, Ewalenko P, Delmotte JJ et, al. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol. 1992;10:52-60.
10. Thom AK, Alexander HR, Andrich MP, et al. Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan. J Clin Oncol. 1995;13:264-273.
11. Seung LP, Mauceri HJ, Beckett MA, et al. Genetic radiotherapy overcomes tumor resistance to cytotoxic agents. Cancer Res. 1995;55:5561-5565.
12. Chung T, Mauceri HJ, Hallahan DE, et al. Tumor necrosis factor-α-based gene therapy enhances radiation cytotoxicity in human prostate cancer. Cancer Gene Ther. 1998;5:344-349.
13. Staba MJ, Mauceru HJ, Kufe DW, et al. Adenoviral TNFα gene therapy and radiation damage tumor vasculature in a human malignant glioma xenograft. Gene Ther. 1988;5:293-300.
14. Gupta VK, Park JO, Jaskowiak NT, et al. Combined gene therapy and ionizing radiation is a novel treatment for human esophageal cancer. J Surg Oncol. 2002 (in press).
15. Brough DE, Lizonova A, Hsu C, et al. A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4. J Firol. 1996;70:6497-6501.
16. Marr RA, Addison CC, Snider D, et al. Tumour immunotherapy using an adenoviral vector expressing a membrane-bound mutant of murine TNF alpha. Gene Ther. 1997;4:1181-1188.
17. Marr RA, Hitt M, Muller WJ, et al. Tumour therapy in mice using adenovirus vectors expressing human TNFα. Int J Oncol. 1998;12:509-515.
18. Marr RA, Hitt M, Gauldie J, et al. A p75 tumor necrosis factor receptor-specific mutant of murine tumor necrosis factor alpha expressed from an adenovirus vector induces an antitumor response with reduced toxicity. Cancer Gene Ther. 1999;6:465-474.
19. Wright P, Braun R, Babiuk L, et al. Adenovirus-based TNF-alpha gene transfer induces significant tumor regression in mice. Cancer Biother Radiopharm. 1999;14:49-57.
20. Hallahan DE, Beckett MA, Kufe D, et al. The interaction between human recombinant tumor necrosis factor and radiation in 13 human tumor cell lines. Int J Radiat Oncol Biol Phys. 1990;19:69-74.
21. Sersa AG, Willingham V, Milas L. Antitumor effects of tumor necrosis factor alone or combined with radiotherapy. Int J Cancer. 1988;42:129-134.
22. Wong GH, McHugh T, Weber R, et al. Tumor necrosis factor selectively sensitizes human immunodeficiency virus-infected cells to heat and radiation. Proc Natl Acad Sci USA. 1991;88:4372-4376.
23. Hidaka C, Milano E, Leopold PL, et al. CAR-dependent and CAR-independent pathways of adenovirus vector-mediated gene transfer and expression in human fibroblast. J Clin Invest. 1999;4:579-587.
24. McDonald D, Stockwin L, Matzow T, et al. Coxsackie and adenovirus receptor (CAR)-dependent and major histocompatibility complex (MHC) class I-independent upstage of recombinant adenoviruses into human tumour cells. Gene Ther. 1999;9:1512-1519.
25. Creaven PJ, Plager JE, Dupere S. Phase I trial of recombinant human tumour necrosis factor. Cancer Chemother Pharmacol. 1997;20:137-144.
26. Talmadge JE, Kaushansky K, Seal GM, et al. Immunomodulatory properties of recombinant murine and human tumor necrosis factor. Cancer Res. 1988;48:544-550.
27. Carswell EA, Old LJ, Kassel RL, et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA. 1975;72:3666-3670.
28. Larick JW, Wright SC. Cytotoxic mechanisms of tumor necrosis factor-alpha. FASEB J. 1994;4:3215-3223.
29. Fiers W. Tumor necrosis factor: Characterization at the molecular, cellular, and in vivo level. FEBS Lett. 1991;285:199-212.
30. Sarraf CE. Tumor necrosis factor and cell death in tumors. Int J Oncol. 1994;5:1333-1339.
31. Benigni F, Faggioni R, Sironi M, et al. TNF receptor p55 plays a major role in centrally mediated increases of serum IL-6 and corticosterone after intracerebroventricular injection of TNF. J Immunol. 1996;157:5563-5568.
32. Vandenabeele P, Declerq W, Vercammen D, et al. Functional characterization of the human tumor necrosis factor receptor p75 in a transfected rat/mouse T cell hybridoma. J Exp Med. 1992;176:1015-1024.
33. Lewis M, Tartaglia LA, Bennett LA, et al. Cloning and expression of a cDNA for two distinct murine tumor necrosis factor receptors demonstrates one receptor is species specific. Proc Natl Acad Sci USA. 1991;88:2830-2834.
34. Erickson SL, de Sauvage FJ, Kikly K, et al. Decreased sensitivity to tumor-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. Nature. 1994;372:560-563.